Developing novel biologics for inflammation and immunology conditions
Jade’s focus is to develop transformational, disease modifying therapies targeting inflammation and immune-related diseases. The company’s lead program, JADE-001, is a potential best-in-class antibody designed to block the APRIL (“A PRoliferation Inducing Ligand”) protein. JADE-001 is anticipated to enter the clinic in the second half of 2025, with initial data expected in the first half of 2026. In addition, our pipeline includes JADE-002 and JADE-003, two undisclosed optimized antibody programs.
|
Program
|
Discovery
|
IND-Enabling
|
Planned Clinical FIH
|
Planned Healthy Volunteer Data
|
|---|---|---|---|---|
| MOA: Anti-aprilJADE-001
|
| 2H25
| 1H26
|
|
|
JADE-001 is a potential best-in-class monoclonal antibody designed to block the APRIL (“A PRoliferation Inducing Ligand”) protein, which plays a key role in the development of IgA nephropathy (IgAN), a chronic kidney disease resulting from inflammation and damage that can impair kidney function over time. By targeting the underlying pathogenesis of IgAN, JADE-001 is designed to reduce IgA levels, lower protein levels in the urine (a key marker of kidney damage), and preserve long-term kidney function. |
||||
| MOA: UndisclosedJADE-002
|
| 1H26
| ||
|
|
||||
| MOA: UndisclosedJADE-003
|
| 1H27
| ||
|
|
||||
JADE-001 is a potential best-in-class monoclonal antibody designed to block the APRIL (“A PRoliferation Inducing Ligand”) protein, which plays a key role in the development of IgA nephropathy (IgAN), a chronic kidney disease resulting from inflammation and damage that can impair kidney function over time. By targeting the underlying pathogenesis of IgAN, JADE-001 is designed to reduce IgA levels, lower protein levels in the urine (a key marker of kidney damage), and preserve long-term kidney function.